ICML 2023 | Epcoritamab monotherapy and combinations in R/R CLL and Richter’s syndrome
Targeting CD20, the bispecific antibody epcoritamab recently received FDA approval for diffuse large B-cell lymphoma (DLBCL) and is now being investigated for chronic lymphocytic leukemia (CLL). In this video, Barbara Eichhorst, MD, University of Cologne, Cologne, Germany, talks on epcoritamab monotherapy and combinations in relapsed/refractory (R/R) CLL and Richter’s syndrome, commenting on the encouraging data garnered from the EPCORE CLL-1 trial (NCT04623541). Dr Eichhorst goes on to talk on the potential of combinatorial strategies with agents such as venetoclax. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
